# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
B. Riley Securities analyst Mayank Mamtani reiterates Cognition Therapeutics (NASDAQ:CGTX) with a Buy and maintains $5 price...
Oppenheimer analyst Jay Olson maintains Cognition Therapeutics (NASDAQ:CGTX) with a Outperform and maintains $9 price target.
Cognition Therapeutics (NASDAQ:CGTX) reported quarterly losses of $(0.27) per share which beat the analyst consensus estimate o...
Companies Reporting Before The Bell • bluebird bio (NASDAQ:BLUE) is likely to report quarterly loss at $0.66 per share on reve...
The Dow Jones index closed lower by more than 100 points on Thursday. When insiders purchase or sell shares, it indicates their...